[{"address1": "Life Science & Technology Park", "address2": "Suite  520 1951 NW 7th Avenue", "city": "Miami", "state": "FL", "zip": "33136", "country": "United States", "phone": "844 470 2550", "website": "https://longeveron.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.", "fullTimeEmployees": 23, "companyOfficers": [{"maxAge": 1, "name": "Dr. Joshua Michael Hare FACC, M.D.", "age": 60, "title": "Co-Founder, Chief Science Officer & Chairman", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 74000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mohamed Wa'el Ahmed Hashad M.B.A.", "age": 61, "title": "CEO & Director", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 867854, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lisa A. Locklear M.B.A.", "age": 62, "title": "CFO & Treasurer", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 472272, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Paul T. Lehr J.D.", "age": 55, "title": "International Executive Director, General Counsel & Secretary", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 554055, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Dan  Gincel Ph.D.", "age": 52, "title": "Senior Vice President of Strategic Collaborations & Scientific Affairs", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Nataliya  Agafonova M.D.", "age": 54, "title": "Chief Medical Officer", "yearBorn": 1969, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lisa  McClain-Moss", "age": 52, "title": "Vice President of Manufacturing", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brian G Rash Ph.D.", "title": "VP of Research & Discovery", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Elly  Ryu", "age": 42, "title": "VP & Corporate Controller", "yearBorn": 1981, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael  Mannarino", "title": "VP & Corporate Controller", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.6, "open": 1.59, "dayLow": 1.59, "dayHigh": 1.72, "regularMarketPreviousClose": 1.6, "regularMarketOpen": 1.59, "regularMarketDayLow": 1.59, "regularMarketDayHigh": 1.72, "beta": 0.349, "forwardPE": -1.0784314, "volume": 293129, "regularMarketVolume": 293129, "averageVolume": 482195, "averageVolume10days": 350020, "averageDailyVolume10Day": 350020, "bid": 1.63, "ask": 1.69, "bidSize": 300, "askSize": 100, "marketCap": 24480720, "fiftyTwoWeekLow": 0.771, "fiftyTwoWeekHigh": 14.8, "priceToSalesTrailing12Months": 19.919218, "fiftyDayAverage": 2.016, "twoHundredDayAverage": 2.2777, "currency": "USD", "enterpriseValue": 22399800, "floatShares": 11186177, "sharesOutstanding": 13352800, "sharesShort": 1277023, "sharesShortPriorMonth": 749645, "sharesShortPreviousMonthDate": 1727654400, "dateShortInterest": 1730332800, "sharesPercentSharesOut": 0.0889, "heldPercentInsiders": 0.10701, "heldPercentInstitutions": 0.03339, "shortRatio": 2.03, "shortPercentOfFloat": 0.1024, "impliedSharesOutstanding": 14836800, "bookValue": 2.685, "priceToBook": 0.61452514, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -27904000, "trailingEps": -5.62, "forwardEps": -1.53, "lastSplitFactor": "1:10", "lastSplitDate": 1711497600, "enterpriseToRevenue": 18.226, "enterpriseToEbitda": -1.301, "52WeekChange": -0.89041096, "SandP52WeekChange": 0.2421279, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "LGVN", "underlyingSymbol": "LGVN", "shortName": "Longeveron Inc.", "longName": "Longeveron Inc.", "firstTradeDateEpochUtc": 1613140200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "0810e7c7-ed9c-3408-947e-be0c34d084bb", "messageBoardId": "finmb_410711455", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.65, "targetHighPrice": 10.0, "targetLowPrice": 6.0, "targetMeanPrice": 8.875, "targetMedianPrice": 9.75, "recommendationKey": "none", "numberOfAnalystOpinions": 4, "totalCash": 12375000, "totalCashPerShare": 0.862, "ebitda": -17219000, "totalDebt": 1748000, "quickRatio": 3.923, "currentRatio": 4.178, "totalRevenue": 1229000, "debtToEquity": 11.723, "revenuePerShare": 0.364, "returnOnAssets": -0.62243, "returnOnEquity": -1.42164, "freeCashflow": -10034000, "operatingCashflow": -16205000, "revenueGrowth": 1.157, "grossMargins": 0.58991003, "operatingMargins": -7.4786296, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-12-21"}]